At the moment the main treatment available for congenital CMV is Ganciclovir. However it is an invasive treatment for a newborn baby (it is administered via intraveinous drip), and in some cases it can cause adverse effects. Also, Ganciclovir treatment must be started before a baby is 4 weeks old, leaving a very small window of opportunity to combat the possible effects of CMV, especially if it is not diagnosed immediately at birth. [singlepic id=59 w=250 float=left]A new study has just been awarded funding to test a less invasive oral antiviral called Valganciclovir. The study will test 6 weeks of valgancyclovir treatment in infants aged 1-18 months old, significantly increasing the potential window for treating congenital CMV. Please email firstname.lastname@example.org if you are interested in finding out more.